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The aim of this study was to assess the relationship between biomarkers (high-sensitive troponin I [hs-TnI], N-Terminal probrain
natriuretic peptide [NT-proBNP]) and calculated 5-year percentage risk score of sudden cardiac death (SCD) in hypertrophic
cardiomyopathy (HCM). Methods. In 46 HCM patients (mean age 39± 7 years, 24 males and 22 females), echocardiographic
examination, including the stimulating maneuvers to provoke maximized LVOT gradient, had been performed and next ECG
Holter was immediately started. After 24 hours, the ECG Holter was finished and the hs-TnI and NT-proBNP have been
measured. Patients were divided according to 1/value of both biomarkers (hs-TnI-positive and hs-TnI-negative subgroups) and
2/(NT-proBNP lower and higher subgroup divided by median). Results. In comparison between 19 patients (hs-TnI positive)
versus 27 patients (hs-TnI negative), the calculated 5-year percentage risk of SCD in HCM was significantly greater (6.38±
4.17% versus 3.81± 3.23%, P < 0 05). In comparison between higher NT-proBNP versus lower NT-proBNP subgroups, the
calculated 5-year percentage risk of SCD in HCM was not significantly greater (5.18± 3.63% versus 4.14± 4.18%, P > 0 05).
Conclusions. Patients with HCM and positive hs-TnI test have a higher risk of SCD estimated according to SCD calculator
recommended by the ESC Guidelines 2014 than patients with negative hs-TnI test.
1. Introduction
The risk factors of sudden cardiac death (SCD) for hypertro-
phic cardiomyopathy (HCM) in the ESC Guidelines [1]
included echocardiogram, electrocardiographic (ECG)Holter
monitoring, and clinical variables. The calculator for sudden
cardiac death risk [1] has not included any biomarker.
Recently, Kehl et al. [2] reviewed the available data regarding
the usefulness of natriuretic peptides and troponins in HCM.
Concentrations of natriuretic peptides, and to a lesser extent
of troponins, correlate with left ventricular thickness, symp-
tom status, and left ventricular hemodynamics by Doppler
measurements (left ventricular filling pressure, left ventricular
outflow tract gradient).
Neither ischemic biomarker nor signs and symptoms of
myocardial ischemia are included in the calculator [1]. How-
ever, ischemic response to stress revealed by echocardio-
graphic methods becomes important prognostic player [3, 4].
Currently used high-sensitivity troponin I (hs-TnI) is an
super precise biomarker for the detection of myocardial
ischemia. In previous HCM studies, measurements of hs-
Tn were only at a resting (without stress in unnatural condi-
tion) echocardiography and not timely synchronized with
maneuvers to provoke LVOTG by natural stimuli reflecting
daily common physical activity for patients [5–8]. Moreover,
measurements of hs-Tn were also not timely synchronized
with the Holter monitoring. So far, we have used the follow-
ing protocol: 24-hour cycle—8 a.m., echocardiography with
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LVOTG provocation by natural stimuli (orthostatic test and
Valsalva test [1, 9–13]; the observation was divided into 2
periods: day phase physical activity with probable episodes
of provocable LVOTG (unmeasurable) and night phase
period as a potential time for rise of troponin, in which the
level has been measured after night at 8 a.m. in the next
day). Between echocardiography and biomarker sampling,
24-hour Holter electrocardiography (ECG) was recorded
and then the measurement of hs-TnI (the biomarker level
has a close temporal relationship with findings on Holter
ECG). This protocol seems to be reasonable because hs-TnI
levels may be a potential cause of life-threatening ventricular
arrhythmias occurring during the previous 24 hours.
The aim of this study was to assess the relationship
between biomarker concentrations (hs-TnI, NT-proBNP)
and calculated 5-year percentage risk score of SCD in HCM.
2. Methods
Consecutive patients with HCM were recruited to the study.
Informed consent was obtained from each participant. All
patients fulfilled conventional diagnostic criteria for HCM.
The criteria for diagnosis of HCM, according to the ESC
Guidelines, were the presence of left ventricular (LV) wall
thickness of at least 15mmwithout any other cause that could
lead to ventricular hypertrophy [1, 13]. The exclusion criteria
were as follows: sport activity more than recreational, prior
myocardial infarction, current symptoms suggestive of coro-
nary artery disease, concomitant neoplasm, infection, or renal
failure. Subjects who had a history of alcohol septal ablation
or septal myectomy were not included into the present study.
The final sample included 46 patients with HCM
(mean± SD age, 39± 7 years; 24 men and 22 women).
Patients on current pharmacotherapy were studied
according to the abovementioned protocol. Patients have
been asked to perform their common day physical activity
and nocturnal resting. This protocol seems to be reasonable
because hs-TnI levels may be related with labile, dynamic
nature of LVOTG with fluctuating peaks in daytime (pro-
voked LVOTG as a potential cause of myocardial ischemia).
2.1. First Model of Risk Calculation (Only the Current ECG
Holter). For calculating the percentage value of HCM risk
score SCD, we assessed the following parameters: episodes
of nonsustained ventricular tachycardia (nsVT) in current
Holter monitoring (defined as three or more consecutive ven-
tricular beats> 120 beats per minute) and two-dimensional
(2D) echocardiography with the assessment of the maximal
left ventricular wall thickness in diastole (MWT), left atrial
diameter (LAD), and maximal provocable left ventricular
outflow tract (LVOT) gradient [1]. For the disease history,
we check the following binary variables: syncope and family
history of sudden death [1]. Finally, we include into the calcu-
lator the age of patients [1].
2.2. Second Model of Risk Calculation (All ECG Holter−
Current +Previous ECG Holter). Every patient had at least 3
times 24-hour ECG Holter recordings during life. One ECG
Holter is defined as current (simultaneous) with biomarker
sampling, and the remaining 2 or more recordings took place
in past history. Presence/absence of NsVT was assessed by
summing the data of all Holter (previous and current). The
remaining parameters used in calculation were identical as
in the first model.
The study protocol was approved by a local institutional
review board (Komisja Bioetyki Jagiellonian University).
2.3. Statistical Analysis. Normally distributed continuous
variables were presented as mean± SD. Differences between
two groups were assessed using independent t-test. Categor-
ical variables were assessed using the Fisher exact test and
expressed as numbers (percentages). A P value of less than
0.05 was considered significant.
3. Results
The baseline characteristics of HCM patients are displayed
in Table 1.
Hs-TnI was detected in all HCM patients and patients
withabnormal level> 19.5 ng/Lweredefinedaspositive tropo-
nin subgroup; nonelevated hs-TnI subgroup consisted of
negative troponin subgroup.AfterNT-proBNPmeasurement,
only 3 patients have a normal concentration< 125 pg/mL;
thus, subgroup division has been created by a median.
In comparison between 19 patients (hs-TnI positive)
versus 27 patients (hs-TnI negative), the calculated 5-year
percentage risk of SCD in HCM was significantly greater,
both in the first and in the second models (Table 2). In
the second comparison between higher NT-proBNP versus
lower NT-proBNP subgroups, the calculated 5-year per-
centage risk of SCD in HCM was not significantly greater
in the first model as well as in the second model (Table 2).
4. Discussion
In the current study, patients with HCM and positive hs-TnI
test have a higher risk of SCD estimated according to SCD
Table 1: Baseline characteristics of the patients.
NYHA class 2.3± 0.6
CCS class 1.5± 0.4
Syncope (n) 15
Sudden death in family history (n) 15
NSVT in current Holter (n) 11
Creatinine, μg/L 82.3± 11.6
Maximum LV thickness, mm 22.5± 4.2
Resting LVOT gradient, ≥30mm Hg (n) 8
Provocable LVOT gradient, ≥30mm Hg (n) 17
Left atrial diameter, mm, mean (SD) 4.83± 0.81
Drugs with negative chronotropic properties (n)
β-Blocker 37
Verapamil 5
None 4
CCS: Canadian Cardiovascular Society; LVOT: left ventricular outflow tract;
LV: left ventricular; NSVT: nonsustained ventricular tachycardia; NYHA:
New York Heart Association.
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calculator recommended by the ESC Guidelines 2014 than
patients with negative hs-TnI test. Level of NT-proBNP is
not associated with the calculated 5-year risk of SCD
(stratified by calculator).
4.1. Clinical Application of Biomarkers in HCM. In a recent
review paper, authors ask the question: NT-proBNP versus
troponin: is one better than the other [2]. Although both bio-
markers correlate with indices of HCM disease progression,
BNP may be a more sensitive indicator of left ventricular
hypertrophy than troponin. It was documented that the wall
thickness threshold was lower for BNP elevation than for
TnI elevation [14]. Moreover, it has also stronger predictors
of hemodynamic parameters and clinical symptoms than
troponin. Although a correlation between elevated troponin
and elevated BNP has been demonstrated [14, 15], it is not a
consistent finding [8, 14].
Before our study, a strategy for application of these bio-
markers to risk stratification has not yet been investigated.
These biomarkers may be most useful when risk markers of
SCD indicate intermediate or indeterminate risk.
The impact of stress echocardiography in HCM is limited
by lack of standardization and outcome data. ECS guidelines
recommend stress echo solely for evaluation of LVOT [3].
However, large-scale registry data show that stress echocardi-
ography positivity for ischemic criteria (such as new wall
motion abnormalities and coronary flow velocity reserve)
rather than inducible gradients predicts adverse outcome
in HCM [4]. In a large study [3], mortality was predicted
using criteria for detecting ischemia on stress echocardiogra-
phy. The investigators proposed that stress echocardiogra-
phy has a signficant prognostic role in patients with HCM,
with ischemic endpoints showing a greater predictive accu-
racy than hemodynamic endpoints [3].
In a recent review by McCarthy et al. [16], the utility of
hs-Tn assessment in arrhythmic disease is only at the initial
stage of investigations, but it has been postulated as a
valuable screening marker for patients with HCM at high
risk of SCD.
Regular training exercise (e.g., fitness activity) has
recently been recommended for selected patients with
HCM [17]. Based on current observation on the association
between tachycardia and elevated troponin level in patients
with HCM [18] and phenomenon of troponin release by
exercise [19], we suggest that any exercise stress test in
HCM patients (performed either for training or diagnostic
purposes) should be controlled by troponin level measure-
ments before exercise and 6 and 12 hours after the exercise.
Especially predisposed to high LVOT gradient are HCM
women> 50 years of age, due to smaller LV cavity size [20].
This subgroup of HCM patients may be particularly at risk
to develop high gradient at peak/post exercise period result-
ing into increased calculated risk in calculator.
Our study has several limitations. First, our study group
may appear too small to definitely rule out association
between NT-proBNP and SCD HCM risk score. Secondly,
the current pharmacological treatment was maintained, and
particularly, β-blockers were not withdrawn. In our pilot
study, we aimed to make the observation on the correlation
between hs-TnI release and timely synchronized findings
on ECG Holter and resting/stress echocardiography.
Our preliminary study showed that β-blocker withdrawal
might not be safe in troponin-positive subgroup of patients.
In future studies, we will attempt to increase the dose and
use only one type of a β-blocker to decrease ischemia burden.
We decided to measure hs-TnI levels only once because
our pilot study was conducted in an outpatient setting. The
optimal protocol, that is, 48-hour profile of troponin
measurement with the assessment of troponin with echocar-
diographic examination every 8 hours, and 48 hours Holter
monitoring (recommended by the ESC Guidelines), would
require the in-hospital setting for the study and would
be more costly. Moreover, only an outpatient-based study
provides an opportunity to assess the heart rate during
Table 2: Comparison between subgroups of hs-TnI positive versus negative and also between subgroup of lower versus higher NT-proBNT
concentration (NS: nonsignificant).
First model—current Holter
Hs-TnI negative
n = 27
Hs-TnI positive
n = 19
5-year SCD risk in HCM 3.81± 3.23% 6.38± 4.17% P < 0 05
Lower NT-proBNP
n = 23
Higher NT-proBNP
n = 23
5-year SCD risk in HCM 4.14± 4.18% 5.18± 3.63% NS
Second model—all Holter
Hs-TnI negative
n = 27
Hs-TnI positive
n = 19
5-year SCD risk in HCM 4.25± 4.20% 6.90± 3.99% P < 0 05
Lower NT-proBNP
n = 23
Higher NT-proBNP
n = 23
5-year SCD risk in HCM 4.40± 3.62% 6.29± 4.18% NS
3Disease Markers
common daily physical activity of patients. At first look, the
study by Kubo et al. [5] seems similar to our study; however,
we have found essential differences from our investigation in
many important points.
(i) Kubo et al. (in pre-era of the ESC Guidelines from
2014, authors did not use calculator risk factors for
SCD) defined their study as analysis of combined
cardiovascular events (with SCD episode [the most
fatal end point] only in 4 patients—such number
seems to be too small for proper statistical analysis).
Our study was not follow-up designed, but focused
on relationship between biomarker levels and calcu-
lated 5-year percentage risk score only for SCD in
HCM. SDC is the most fatal, but an easy preventable
complication of HCM (by ICD).
(ii) Morphologic/prognostic differences are also impor-
tant (in Kubo et al., patients had less predisposition
for SCD: a benign apical variant 28% versus 0% in
our group). The benign morphologic pattern in
Kubo et al. paper seems to correspond to the low
number of SCD.
(iii) In Kubo et al., LVOT gradient was assessed in binary
analysis< 30mmHg or ≥30mmHg and only in
resting conditions. In contrast, we have assessed
LVOTG more precisely as a continuous variable,
measured both at rest and after provocation (the
provocable LVOTG is absolutely needed to measure
risk of SCD by ESC calculator).
(iv) Kubo et al. did not analyze nsVT in ECG-Holter
(which is absolutely needed to measure the risk of
SCD by calculator); moreover, nsVT assessment is
needed also in the American Guideline from 2011
for risk stratification of SDC. Thus, in a paper
by Kubo et al., the lack of ECG Holter analysis
is a serious limitation.
(v) Kubo et al. did not describe the time period between
blood sampling for biomarkers and measurement of
echo parameters (nsVT in Holter was not studied).
In our study, the time synchrony between echo/
Holter and hs-TnI measurement was defined.
(vi) Kubo et al. did not analyze NT-proBNP, but only hs-
Tn. Our study provides more information about two
important biomarker sampling simultaneously with
echocardiographic and ECG Holter measurements.
5. Conclusions
Patients with HCM and positive hs-TnI test have higher risk
of SCD estimated according to SCD calculator recommended
by the ESC Guidelines 2014 than patients with negative
hs-TnI test.
5.1. Clinical Perspective. These findings suggest that hs-Tn
may be useful as an additional biomarker for better risk
stratification in HCM. Additionally, we have postulated to
monitor also the biomarkers of endothelial dysfunction
(impaired endothelium-dependent vasodilatation) [21].
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